Navigation Links
Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
Date:1/31/2012

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), has released upgrades to its electronic data capture system SynCapture™, providing customers with increased user functionality. SynCapture allows for clinical study data to be captured into a single database using multiple modes of entry including paper, fax, and web based, resulting in more seamless, flexible and cost effective data capture.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

"We understand that low cost EDC is critical, especially in smaller trials," said Wendel Barr, chief executive officer at Synteract. "SynCapture has been an effective solution to handle the needs of our clients since it was first implemented in 2005.  SynCapture 1.5 integrates features that enhance our cost efficient EDC offering, so we can continue to meet each client's unique program requirements."

SynCapture 1.5 provides users the ability to re-query investigative sites on data collected, an upgrade sponsors requested. In addition, the new release brings enhanced audit trail legibility and functionality useful to all project team members, as well as features that increase the ease and efficiency of the query resolution process.

"SynCapture 1.5 provides users increased functionality and easier data collection," said Olivia Montano, senior director of clinical data management at Synteract. "The main reason for the upgrade was to improve the user experience.  We took into account direct requests from users, since customer service is so integral to what we do at Synteract. This SynCapture upgrade allows us to provide clients an improved option for on-time delivery of quality data to help them get to decision points faster."

About Synteract, Inc.

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424

 


'/>"/>
SOURCE Synteract, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):